Published in:
17-08-2023 | Glioma | short review
ASCO 2023: new treatment options in CNS tumors
Invited short review
Published in: memo - Magazine of European Medical Oncology | Issue 4/2023
Login to get accessSummary
Practice-changing therapy for IDH1/2–mutant diffuse glioma was presented at the meeting. Vorasidenib as an oral, brain penetrant, dual inhibitor of mutant IDH1/2 showed very promising results in the phase 3 INDIGO study. Other new treatment approaches including vaccines, immunotherapy and targeted therapy in rare von Hippel–Lindau-associated cerebral hemangioblastomas have shown progress in neuro-oncology.